Agios Pharmaceuticals (AGIO) Expected to Announce Quarterly Earnings on Thursday

Agios Pharmaceuticals (NASDAQ:AGIO) is anticipated to post its Q4 2025 results before the market opens on Thursday, February 12th. Analysts expect the company to announce earnings of ($1.96) per share and revenue of $12.0590 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, February 12, 2026 at 8:00 AM ET.

Agios Pharmaceuticals Stock Down 0.8%

NASDAQ AGIO opened at $27.70 on Thursday. The stock has a market capitalization of $1.62 billion, a P/E ratio of -3.96 and a beta of 0.91. Agios Pharmaceuticals has a 52-week low of $22.24 and a 52-week high of $46.00. The firm has a 50-day moving average price of $27.49 and a 200 day moving average price of $34.63.

Analyst Upgrades and Downgrades

Several research firms have recently commented on AGIO. JPMorgan Chase & Co. raised their price target on Agios Pharmaceuticals from $20.00 to $25.00 and gave the company a “neutral” rating in a report on Tuesday, January 6th. Citigroup reiterated a “buy” rating on shares of Agios Pharmaceuticals in a research report on Friday, December 26th. Royal Bank Of Canada downgraded Agios Pharmaceuticals from an “outperform” rating to a “sector perform” rating and dropped their price objective for the company from $57.00 to $28.00 in a research note on Wednesday, November 19th. Bank of America lifted their price objective on Agios Pharmaceuticals from $32.00 to $34.00 and gave the stock a “buy” rating in a report on Wednesday, December 24th. Finally, Wall Street Zen lowered Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, November 22nd. Six equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Agios Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $39.44.

Insider Activity

In other news, insider Sarah Gheuens sold 2,932 shares of Agios Pharmaceuticals stock in a transaction dated Tuesday, December 30th. The shares were sold at an average price of $27.09, for a total transaction of $79,427.88. Following the completion of the sale, the insider directly owned 64,795 shares in the company, valued at $1,755,296.55. The trade was a 4.33% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider James William Burns sold 2,932 shares of the business’s stock in a transaction that occurred on Tuesday, December 30th. The shares were sold at an average price of $27.09, for a total transaction of $79,427.88. Following the completion of the transaction, the insider directly owned 31,718 shares of the company’s stock, valued at approximately $859,240.62. This represents a 8.46% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 33,503 shares of company stock worth $910,745 in the last quarter. Corporate insiders own 4.30% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in AGIO. AQR Capital Management LLC increased its stake in Agios Pharmaceuticals by 66.8% in the first quarter. AQR Capital Management LLC now owns 51,489 shares of the biopharmaceutical company’s stock valued at $1,498,000 after purchasing an additional 20,625 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Agios Pharmaceuticals by 7.2% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,327 shares of the biopharmaceutical company’s stock valued at $1,274,000 after buying an additional 2,920 shares during the period. NewEdge Advisors LLC purchased a new position in shares of Agios Pharmaceuticals in the 1st quarter worth $40,000. Goldman Sachs Group Inc. grew its position in Agios Pharmaceuticals by 16.1% during the first quarter. Goldman Sachs Group Inc. now owns 658,652 shares of the biopharmaceutical company’s stock valued at $19,299,000 after acquiring an additional 91,482 shares during the period. Finally, Woodline Partners LP purchased a new stake in Agios Pharmaceuticals during the first quarter valued at about $597,000.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.